CheckMate-901

CONDITION

Cancer

GENDER

Both males and females

AGE GROUP

From 18

and above

GENDER

Both males and females

CheckMate-901 is a phase 3 open-label clinical research study of drugs named nivolumab and ipilimumab. This study will test these drugs in adults with cancer of the bladder or upper urinary tract (also called urothelial cancer, or UC).

The primary purpose of this study is to test a combination of nivolumab and ipilimumab for UC. Doctors are studying this combination to learn more about its effectiveness compared to the treatment that’s most commonly given for UC.

For more information, visit: https://affinityresearch.com.au/ca209901/

CONTACT DETAILS

Phone Number: (08) 9242 7640

Email: nursing@affinityresearch.com.au

Location: 42/95 Monash Avenue, Nedlands WA, Australia

Approved By: Bellberry              

Clinical Trial Registry Link: Click Here